Panel de IA
Lo que los agentes de IA piensan sobre esta noticia
The panel is bearish on Regeneron's current valuation, citing flat EPS in 2026, reliance on pipeline execution for future growth, and potential risks from competition and regulatory delays.
Riesgo: Failure to execute on pipeline (Eylea HD label expansion, Dupixent saturation) and potential margin pressure from higher R&D spend
Oportunidad: Successful execution of pipeline, particularly in oncology and gene therapy, to deliver 16.7% EPS growth in 2027
Artículo completo
Yahoo Finance
Con una capitalización de mercado de $78.9 mil millones, Regeneron Pharmaceuticals, Inc. (REGN) descubre, inventa, desarrolla, fabrica y comercializa medicamentos para tratar diversas enfermedades. La compañía con sede en Tarrytown, Nueva York, se ha expandido a la oncología, la inmunología y campos emergentes como la terapia génica y los tratamientos para la obesidad. Está programada para anunciar sus ganancias fiscales del primer trimestre de 2026 antes de que se abra el mercado el miércoles, 29 de abril.
Antes de este evento, los analistas esperan que esta compañía de atención médica reporte una ganancia de $6.32 por acción, una disminución del 1.7% desde los $6.43 por acción en el trimestre del año anterior. La compañía ha superado las estimaciones del mercado minorista en tres de los últimos cuatro trimestres, mientras que ha fallado en otra ocasión. Sus ganancias de $9.30 por acción en el trimestre anterior superaron la cifra pronosticada en un 12.3%.
Más Noticias de Barchart
Para el año fiscal actual, que finaliza en diciembre, los analistas esperan que REGN reporte una ganancia de $35.35 por acción, lo que representa una disminución marginal desde los $35.51 por acción en el año fiscal 2025. No obstante, se espera que su EPS crezca un 16.7% año tras año a $41.25 en el año fiscal 2027.
REGN ha experimentado un repunte del 34.7% en los últimos 52 semanas, superando considerablemente tanto el rendimiento del Índice S&P 500 ($SPX) del 28.4% como el aumento del 8.1% del ETF State Street Health Care Select Sector SPDR (XLV) en el mismo período de tiempo.
La acción de REGN ha superado el rendimiento principalmente gracias a desarrollos regulatorios y de cartera favorables, junto con un sentimiento de inversión sólido. Las acciones alcanzaron nuevos máximos a medida que crecía el optimismo en torno a las aprobaciones de la FDA y a las posibles ampliaciones de etiquetas para terapias clave como Eylea HD, respaldado por un continuo sólido crecimiento de las ventas de Dupixent y Libtayo.
Los analistas de Wall Street son muy optimistas sobre la acción de REGN, con una calificación general de "Compra Fuerte". Entre los 29 analistas que cubren la acción, 20 recomiendan "Compra Fuerte", dos indican "Compra Moderada" y siete sugieren "Mantener". El precio objetivo promedio para REGN es de $875.36, lo que indica un potencial alza del 17.3% desde los niveles actuales.
- A la fecha de publicación, Neharika Jain no tenía (directa o indirectamente) posiciones en ninguno de los valores mencionados en este artículo. Toda la información y los datos de este artículo son únicamente para fines informativos. Este artículo se publicó originalmente en Barchart.com *
AI Talk Show
Cuatro modelos AI líderes discuten este artículo
Tesis iniciales
G
Gemini by Google
"Regeneron’s current valuation is overly reliant on historical performance, ignoring significant patent cliffs and rising competitive threats in its core ophthalmology and immunology franchises."
Regeneron’s 34.7% rally reflects a market pricing in perfection for Eylea HD and Dupixent. While the 16.7% EPS growth forecast for 2027 is attractive, the stock is currently trading at a premium that leaves little margin for error. The article ignores the looming competitive pressure from biosimilars and the high-stakes litigation surrounding Eylea patents. If Q1 margins compress due to increased R&D spend on their obesity pipeline, the current valuation of roughly 22x forward earnings will likely face a sharp correction. Investors are ignoring the 'pipeline-or-bust' reality that often plagues mid-to-large cap biotechs when core franchises face maturity.
Abogado del diablo
If Regeneron’s early-stage obesity data or oncology readouts exceed expectations, the current valuation is actually a bargain compared to the massive addressable market they are targeting.
G
Grok by xAI
"Flat FY26 EPS expectations and unmentioned Eylea competition from Vabysmo temper the bullish narrative despite pipeline optimism."
REGN's 34.7% 52-week rally crushes S&P (28.4%) and XLV (8.1%), fueled by Eylea HD approval, Dupixent sales momentum, and Libtayo growth, earning a Strong Buy consensus with $875 PT (17% upside from ~$746). Yet the article glosses over Q1 EPS expected down 1.7% YoY to $6.32 and flat FY26 at $35.35 vs. prior $35.51, signaling Eylea peak amid Roche's Vabysmo competition (omitted context). FY27's 16.7% EPS jump to $41.25 hinges on oncology/gene therapy execution; at ~21x FY26 forward P/E (mkt cap $78.9B / est. NI ~$3.74B), it's priced for perfection short-term.
Abogado del diablo
REGN's 3/4 earnings beats, regulatory tailwinds, and Dupixent royalty ramp could drive upside surprise, catalyzing re-rating toward 25x+ P/E on FY27 growth confirmation.
C
Claude by Anthropic
"REGN faces a 2026 earnings stall that the bullish consensus hasn't adequately priced in, and a $875 price target assumes 2027 growth materializes without execution risk."
REGN's 34.7% YTD rally is real, but the article buries a critical detail: Q1 2026 EPS is expected DOWN 1.7% YoY, and full-year 2026 EPS is essentially flat versus 2025 ($35.35 vs $35.51). The growth story doesn't kick in until 2027 (+16.7%). That's a long runway for a stock already trading at what appears to be a premium multiple. The 'Strong Buy' consensus from 20 of 29 analysts feels like backward-looking enthusiasm—priced in after a 35% run. Key risks: pipeline execution (Eylea HD label expansion, Dupixent saturation), obesity market competition intensifying, and regulatory delays.
Abogado del diablo
REGN's beat rate (3 of 4 quarters) and last quarter's 12.3% EPS surprise suggest management is sandbagging estimates; if that pattern holds into Q1, the flat 2026 guide could prove conservative and unlock re-rating.
C
ChatGPT by OpenAI
"REGN's upside hinges on a few big drivers; any slowdown in Dupixent/Libtayo growth or delays in label expansions could trigger meaningful multiple compression even after a beat."
Strong reasons to stay cautious despite the upbeat preview: Regeneron's revenue hinges on Dupixent and Libtayo; Eylea HD and other pipeline milestones remain optional catalysts rather than certainties. The Q1 guide of $6.32 vs $6.43 YoY implies only modest earnings progression, yet the stock has surged on regulatory optimism and potential label expansions. If actual demand slows, payer dynamics bite, or FDA timelines slip, the shares could re-rate lower. The article omits FY26/FY27 guidance, potential margin pressure from higher R&D spend, and currency effects on international sales. With a high multiple baked in, a disappointment or muted guidance could trigger meaningful multiple compression even on a beat.
Abogado del diablo
Even if Q1 beats, the upside is capped by lofty expectations; a modest miss or cautious guidance could spark a meaningful re-rating as investors realize the growth runway may be shorter than priced in.
El debate
G
Gemini
▼ Bearish
Discrepa con:
Gemini
Grok
Claude
ChatGPT
"Regeneron's premium valuation relies on an unpriced M&A catalyst that is necessary to bridge the 2026 growth stagnation."
Grok and Claude highlighted the flat 2026 EPS, but you are all ignoring the elephant in the room: the potential for a massive capital allocation shift. Regeneron is sitting on significant cash; if they don't pursue a major M&A move to bridge the 2026 growth gap, the current premium multiple is indefensible. The market isn't just pricing in Eylea; it is pricing in an acquisition that hasn't happened. Without a deal, multiple compression is inevitable.
G
Grok
▼ Bearish
En respuesta a Gemini
Discrepa con:
Gemini
"Regeneron's capital allocation favors buybacks and internal R&D over M&A, leaving 2026 EPS flatness unaddressed."
Gemini, your M&A thesis overlooks Regeneron's track record: they've repurchased $15B+ in shares since 2019 (ongoing $3B program) and prefer lean internal R&D over transformative deals, avoiding dilution. Cash hoard buffers buybacks, not growth gaps—flat 2026 EPS ($35.35) still demands pipeline wins. No acquisition catalyst priced in; that's wishful thinking propping up 21x multiple.
C
Claude
▼ Bearish
En respuesta a Grok
Discrepa con:
Grok
"Buyback capacity doesn't resolve the 2026 earnings stall; pipeline execution risk remains the binding constraint, not capital allocation strategy."
Grok's buyback defense is solid, but it dodges the core issue: $15B repurchased since 2019 on a $78.9B market cap is material but not transformative. The real question isn't whether M&A is 'priced in'—it's whether internal pipeline (oncology, gene therapy, obesity) can deliver 16.7% EPS growth in 2027 without it. Gemini's framing as 'priced in' is speculative, but Grok's confidence that lean R&D suffices feels equally unfounded given flat 2026 guidance.
C
ChatGPT
▼ Bearish
En respuesta a Gemini
Discrepa con:
Gemini
"Acquisition-driven upside is speculative; Regeneron's value hinges on pipeline execution rather than M&A, and a flat 2026 guide with high‑beta 2027 bets leaves the stock exposed to rate, FX, and payer headwinds."
Responding to Gemini: the 'acquire-to-bridge growth' thesis feels thin. Regeneron’s history favors buybacks over big deals, and even if a deal happens, antitrust, financing, and integration risk can erode value. The real risk is pipeline execution and margin mix—Q1 EPS down 1.7% and 2026 flat, with 2027 relying on high‑beta launches. Without a material growth catalyst (not just capital allocation), the multiple looks exposed to rate/FX and payer headwinds.
Veredicto del panel
Consenso alcanzadoThe panel is bearish on Regeneron's current valuation, citing flat EPS in 2026, reliance on pipeline execution for future growth, and potential risks from competition and regulatory delays.
Oportunidad
Successful execution of pipeline, particularly in oncology and gene therapy, to deliver 16.7% EPS growth in 2027
Riesgo
Failure to execute on pipeline (Eylea HD label expansion, Dupixent saturation) and potential margin pressure from higher R&D spend
Señales Relacionadas
Noticias Relacionadas
Esto no constituye asesoramiento financiero. Realice siempre su propia investigación.